Upadacitinib Treatment Outcomes in Crohn’s Disease: A Retrospective Analysis of Clinical Response and Perianal Fistula Resolution
Authors:
- Junya ShiotaJSJunya Shiota
- Moto KitayamaMKMoto Kitayama
- Hiroko InomataHIHiroko Inomata
- Taro AkashiTATaro Akashi
- Maiko TabuchiMTMaiko Tabuchi
- Keiichi HashiguchiKHKeiichi Hashiguchi
- Kayoko MatsushimaKMKayoko Matsushima
- Yuko AkazawaYAYuko Akazawa
- Naoyuki YamaguchiNYNaoyuki Yamaguchi
- Hisamitsu MiyaakiHMHisamitsu Miyaaki
Open Access
- 1 January 2026
- journal article
- Published by S. Karger AG in Inflammatory Intestinal Diseases
- Vol. 11 (1) , 100-109
Abstract
Introduction: Upadacitinib (UPA), a Janus kinase inhibitor approved for the treatment of Crohn’s disease (CD), has demonstrated high efficacy in clinical trials; however, real-world data on its outcomes remain limited. This study evaluated UPA outcomes in patients with CD in a real-world setting. Methods: We retrospectively analyzed patients who initiated UPA treatment between June 2023 and June 2024. The primary endpoints were clinical response and remission at 12 and 54 weeks. The secondary endpoints included changes in the C-reactive protein (CRP) levels, serum albumin levels, and perianal fistula response. Results: Thirteen patients (mean age, 32.0 years; 92.3% male; mean disease duration, 114.1 months) were included. At baseline, three (23.1%) patients used oral corticosteroids, and 11 (84.6%) had undergone prior biologic therapy, with nine (81.8%) exposed to anti-tumor necrosis factor-alpha antibodies. The mean follow-up period was 53.1 weeks, and the 54-week continuation rate was 83.3%. The clinical response rates were 46.2% and 53.8%, and the remission rates were 69.2% and 84.6% at 12 and 54 weeks, respectively. The mean Crohn’s Disease Activity Index scores decreased from 226.8 at baseline to 73.7 at 54 weeks, and the average CRP and albumin levels improved correspondingly. Among the 7 patients (53.8%) with draining perianal fistulas, six (85.7%) achieved cessation of pus discharge by week 8 (mean, 4.4 weeks). No significant adverse events were observed. Conclusion: UPA appears to be an effective treatment for CD and may facilitate the early resolution of perianal fistulas, supporting its role in managing perianal disease.Keywords
This publication has 33 references indexed in Scilit:
- Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto ConsensusInflammatory Bowel Diseases, 2018
- Anti-TNF Therapy in Crohn’s DiseaseInternational Journal of Molecular Sciences, 2018
- MR Imaging of Perianal Crohn DiseaseRadiology, 2017
- Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical managementAlimentary Pharmacology & Therapeutics, 2015
- Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)Gut, 2013
- [Quality of life of Crohn's disease patients].2009
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- The quality of life in patients with Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999